Modulation of death receptor 4 in EGFR-targeted cancer therapy

EGFR 靶向癌症治疗中死亡受体 4 的调节

基本信息

  • 批准号:
    10006518
  • 负责人:
  • 金额:
    $ 43.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-09 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Targeting epidermal growth factor receptor (EGFR) activating mutations, 90% of which present as an exon 19 deletion (Del19) or exon 21 point mutation (L858R), with first generation EGFR tyrosine kinase inhibitors (EGFR-TKIs; e.g., erlotinib and gefitinib) and the T790M resistance mutation with third generation EGFR-TKIs (e.g., AZD9291; TAGRISSOTM or osimertinib) has provided significant clinical benefit in patients with non-small cell lung cancer (NSCLC) harboring these mutations. Unfortunately, resistance to these EGFR-TKIs occurs in the clinic, resulting in disease progression. Hence, understanding the underlying mechanisms and developing effective strategies to overcome EGFR-TKI resistance is highly desirable and urgently needed in the clinic. Death receptor 4 (DR4; also known as TRAIL-R1 or TNFRSF10A) is a cell surface receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). It is generally thought that its activation, upon binding to TRAIL, induces apoptosis; this function is recognized as a critical mechanism of immunosurveillance against cancer cells. However, whether DR4 exerts other as yet unknown biological functions is unclear. Our preliminary data demonstrated that EGFR inhibition with several EGFR inhibitors including AZD9291, CO1686, and erlotinib substantially decreased DR4 levels primarily in EGFR-TKI-sensitive EGFR-mutant NSCLC cell lines; this DR4 reduction is tightly associated with ERK suppression and induction of apoptosis in the tested cell lines. Unexpectedly, knockdown of DR4 augments TRAIL-induced apoptosis and also enhances AZD9291- induced apoptosis. This proposal thus will test the overall hypothesis that suppression of DR4 expression is an on-target consequence of EGFR inhibition and has critical impact on both early and long-term therapeutic efficacy of EGFR-targeted therapy. This hypothesis will be tested by accomplishing the following specific aims: (1) to demonstrate the mechanism(s) by which EGFR inhibitors suppress DR4 expression; (2) to understand the biological significance of DR4 suppression in EGFR-targeted cancer therapy; and (3) to elucidate the effect of DR4 downregulation on the efficacy of EGFR-targeted therapy using preclinical NSCLC patient-derived xenografts (PDXs) and samples from NSCLC patients treated with EGFR-TKIs. The objectives of this proposal are to demonstrate the molecular mechanism underlying DR4 reduction caused by EGFR inhibition, to understand the biological significance of DR4 suppression in EGFR-targeted cancer therapy, and to validate DR4 downregulation in clinical specimens from NSCLC patients receiving EGFR-TKIs. We believe that the outcomes of this proposal will be of high translational significance with immediate impact on EGFR-targeted cancer therapy in the clinic. 1
靶向表皮生长因子受体(EGFR)激活突变,其中90%作为外显子19存在 缺失(Del 19)或21号外显子点突变(L 858 R),使用第一代EGFR酪氨酸激酶抑制剂 (EGFR-TKI;例如,厄洛替尼和吉非替尼)和第三代EGFR-TKI的T790 M耐药突变 (e.g., AZD 9291; TAGRISSO TM或奥希替尼)在非小细胞肺癌患者中提供了显著的临床获益。 细胞肺癌(NSCLC)携带这些突变。不幸的是,对这些EGFR-TKI的耐药性发生在 临床,导致疾病进展。因此,了解潜在的机制和开发 克服EGFR-TKI抗性的有效策略在临床上是非常期望和迫切需要的。 死亡受体4(DR 4;也称为TRAIL-R1或TNFRSF 10A)是肿瘤坏死的细胞表面受体 因子相关凋亡诱导配体(TRAIL)。一般认为,当与蛋白质结合时, TRAIL诱导细胞凋亡;该功能被认为是针对肿瘤的免疫监视的关键机制。 癌细胞然而,DR 4是否发挥其他未知的生物学功能尚不清楚。我们 初步数据表明,用包括AZD 9291,CO 1686, 和厄洛替尼显著降低DR 4水平,主要在EGFR-TKI敏感性EGFR突变型NSCLC细胞中 DR 4的减少与ERK抑制和细胞凋亡的诱导密切相关。 细胞系出乎意料的是,DR 4的敲低增强了TRAIL诱导的细胞凋亡,也增强了AZD 9291的表达。 诱导凋亡。因此,该提议将检验抑制DR 4表达是一种治疗癌症的有效方法的总体假设。 EGFR抑制的靶向结果,并对早期和长期治疗 EGFR靶向治疗的疗效。将通过实现以下具体目标来检验这一假设: (1)证明EGFR抑制剂抑制DR 4表达的机制;(2)了解 DR 4抑制在EGFR靶向癌症治疗中的生物学意义;(3)阐明DR 4抑制对EGFR靶向癌症治疗的影响。 DR 4下调对EGFR靶向治疗疗效的影响 异种移植物(PDX)和来自用EGFR-TKI治疗的NSCLC患者的样品。本提案的目标 旨在证明EGFR抑制导致DR 4降低的分子机制, 了解EGFR靶向癌症治疗中DR 4抑制的生物学意义,并验证 接受EGFR-TKI治疗的NSCLC患者临床标本中的DR 4下调。我们认为 这项建议的结果将具有高度的转化意义,对EGFR靶向的 癌症治疗在诊所 1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shi-Yong Sun其他文献

Shi-Yong Sun的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shi-Yong Sun', 18)}}的其他基金

c-Myc modulation and its implications in EGFR-targeted cancer therapy
c-Myc 调节及其对 EGFR 靶向癌症治疗的影响
  • 批准号:
    10427217
  • 财政年份:
    2020
  • 资助金额:
    $ 43.91万
  • 项目类别:
c-Myc modulation and its implications in EGFR-targeted cancer therapy
c-Myc 调节及其对 EGFR 靶向癌症治疗的影响
  • 批准号:
    10212350
  • 财政年份:
    2020
  • 资助金额:
    $ 43.91万
  • 项目类别:
c-Myc modulation and its implications in EGFR-targeted cancer therapy
c-Myc 调节及其对 EGFR 靶向癌症治疗的影响
  • 批准号:
    10649650
  • 财政年份:
    2020
  • 资助金额:
    $ 43.91万
  • 项目类别:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
EGFR 靶向癌症治疗中死亡受体 4 的调节
  • 批准号:
    10524101
  • 财政年份:
    2018
  • 资助金额:
    $ 43.91万
  • 项目类别:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
EGFR 靶向癌症治疗中死亡受体 4 的调节
  • 批准号:
    10653881
  • 财政年份:
    2018
  • 资助金额:
    $ 43.91万
  • 项目类别:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
EGFR 靶向癌症治疗中死亡受体 4 的调节
  • 批准号:
    10206047
  • 财政年份:
    2018
  • 资助金额:
    $ 43.91万
  • 项目类别:
Modulation of death receptor 4 in EGFR-targeted cancer therapy
EGFR 靶向癌症治疗中死亡受体 4 的调节
  • 批准号:
    10428557
  • 财政年份:
    2018
  • 资助金额:
    $ 43.91万
  • 项目类别:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
mTOR 激酶抑制剂在肺癌中的治疗潜力
  • 批准号:
    8624748
  • 财政年份:
    2012
  • 资助金额:
    $ 43.91万
  • 项目类别:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
mTOR 激酶抑制剂在肺癌中的治疗潜力
  • 批准号:
    8639500
  • 财政年份:
    2012
  • 资助金额:
    $ 43.91万
  • 项目类别:
Therapeutic potential of mTOR kinase inhibitors in lung cancer
mTOR 激酶抑制剂在肺癌中的治疗潜力
  • 批准号:
    8825457
  • 财政年份:
    2012
  • 资助金额:
    $ 43.91万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 43.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了